Immunobiology of carcinoma of the prostate

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Limited evidence suggests that prostatic cancer cells express antigens that are immunogenic in the host. Some of these tumor-associated antigens are fetal antigens and others may be oncogenic viral-induced tumor antigens. In addition, both benign and malignant prostatic epithelial cells produce an antigenically distinctive form of acid phosphatase, but it is unknown whether acid phosphatase can function as a target for cytotoxic mechanisms. There is ample evidence that host cell-mediated immunologic activity is depressed in many prostatic cancer patients. The mechanisms underlying these impairments are unclear, but a number of factors has been implicated including uncharacterized 'serum blockers', alpha-2 globulins, and circulating antigen-antibody complexes. Endocrine manipulations can also alter host immune mechanisms. There is some evidence to suggest that host immune competence correlates inversely with tumor progression in patients who have relapsed after endocrine therapy. Immunotherapy for prostatic cancer has not been adequately studied. There have been a few inconclusive attempts at active immunotherapy using bacille Calmette Guerin and cryosurgery and virtually no attempts at passive immunotherapy. The future prospects for immunology as a useful tool in the management of prostatic cancer patients are discussed.

Original languageEnglish (US)
Pages (from-to)373-377
Number of pages5
JournalInvestigative Urology
Volume17
Issue number5
StatePublished - Jan 1 1980

Fingerprint

Prostate
Prostatic Neoplasms
Carcinoma
Acid Phosphatase
Alpha-Globulins
Antigens
Active Immunotherapy
Cryosurgery
Passive Immunization
Viral Tumor Antigens
Neoplasm Antigens
Allergy and Immunology
Antigen-Antibody Complex
Immunotherapy
Mental Competency
Epithelial Cells
Serum
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{045e078d09134510bb72c057a4382576,
title = "Immunobiology of carcinoma of the prostate",
abstract = "Limited evidence suggests that prostatic cancer cells express antigens that are immunogenic in the host. Some of these tumor-associated antigens are fetal antigens and others may be oncogenic viral-induced tumor antigens. In addition, both benign and malignant prostatic epithelial cells produce an antigenically distinctive form of acid phosphatase, but it is unknown whether acid phosphatase can function as a target for cytotoxic mechanisms. There is ample evidence that host cell-mediated immunologic activity is depressed in many prostatic cancer patients. The mechanisms underlying these impairments are unclear, but a number of factors has been implicated including uncharacterized 'serum blockers', alpha-2 globulins, and circulating antigen-antibody complexes. Endocrine manipulations can also alter host immune mechanisms. There is some evidence to suggest that host immune competence correlates inversely with tumor progression in patients who have relapsed after endocrine therapy. Immunotherapy for prostatic cancer has not been adequately studied. There have been a few inconclusive attempts at active immunotherapy using bacille Calmette Guerin and cryosurgery and virtually no attempts at passive immunotherapy. The future prospects for immunology as a useful tool in the management of prostatic cancer patients are discussed.",
author = "Catalona, {W. J.}",
year = "1980",
month = "1",
day = "1",
language = "English (US)",
volume = "17",
pages = "373--377",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

Immunobiology of carcinoma of the prostate. / Catalona, W. J.

In: Investigative Urology, Vol. 17, No. 5, 01.01.1980, p. 373-377.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Immunobiology of carcinoma of the prostate

AU - Catalona, W. J.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - Limited evidence suggests that prostatic cancer cells express antigens that are immunogenic in the host. Some of these tumor-associated antigens are fetal antigens and others may be oncogenic viral-induced tumor antigens. In addition, both benign and malignant prostatic epithelial cells produce an antigenically distinctive form of acid phosphatase, but it is unknown whether acid phosphatase can function as a target for cytotoxic mechanisms. There is ample evidence that host cell-mediated immunologic activity is depressed in many prostatic cancer patients. The mechanisms underlying these impairments are unclear, but a number of factors has been implicated including uncharacterized 'serum blockers', alpha-2 globulins, and circulating antigen-antibody complexes. Endocrine manipulations can also alter host immune mechanisms. There is some evidence to suggest that host immune competence correlates inversely with tumor progression in patients who have relapsed after endocrine therapy. Immunotherapy for prostatic cancer has not been adequately studied. There have been a few inconclusive attempts at active immunotherapy using bacille Calmette Guerin and cryosurgery and virtually no attempts at passive immunotherapy. The future prospects for immunology as a useful tool in the management of prostatic cancer patients are discussed.

AB - Limited evidence suggests that prostatic cancer cells express antigens that are immunogenic in the host. Some of these tumor-associated antigens are fetal antigens and others may be oncogenic viral-induced tumor antigens. In addition, both benign and malignant prostatic epithelial cells produce an antigenically distinctive form of acid phosphatase, but it is unknown whether acid phosphatase can function as a target for cytotoxic mechanisms. There is ample evidence that host cell-mediated immunologic activity is depressed in many prostatic cancer patients. The mechanisms underlying these impairments are unclear, but a number of factors has been implicated including uncharacterized 'serum blockers', alpha-2 globulins, and circulating antigen-antibody complexes. Endocrine manipulations can also alter host immune mechanisms. There is some evidence to suggest that host immune competence correlates inversely with tumor progression in patients who have relapsed after endocrine therapy. Immunotherapy for prostatic cancer has not been adequately studied. There have been a few inconclusive attempts at active immunotherapy using bacille Calmette Guerin and cryosurgery and virtually no attempts at passive immunotherapy. The future prospects for immunology as a useful tool in the management of prostatic cancer patients are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0018883924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018883924&partnerID=8YFLogxK

M3 - Review article

VL - 17

SP - 373

EP - 377

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -